Laura Tan

Laura Tan

Auto-generated profile, based on publicly available information

Laura Tan

Department of Anaesthesia, Intensive Care and Pain Medicine, Division of Population Medicine, Cardiff University, Cardiff CF14 4XN, UK

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MAMohammad Alsallakh
Mohammad Alsallakh
LTLaura Tan
Laura Tan
RPRichard Pugh
Richard Pugh
AAAshley Akbari
Ashley Akbari
RBRowena Bailey
Rowena Bailey
Tamas SzakmanyTamas Szakmany
Tamas Szakmany
In this retrospective cohort study, we used the Secure Anonymised Information Linkage (SAIL) Databank to characterise and identify predictors of the one-year post-discharge healthcare resource utilisation (HRU) of adults who were admitted to critical care units in Wales between 1 April 2006 and 31 December 2017. We modelled one-year post-critical-care HRU using negative binomial models and used linear models for the difference from one-year pre-critical-care HRU. We estimated the association between critical illness and post-hospitalisation HRU using multilevel negative binomial models among people hospitalised in 2015. We studied 55,151 patients. Post-critical-care HRU was 11–87% greater than pre-critical-care levels, whereas emergency department (ED) attendances decreased by 30%. Age ≥50 years was generally associated with greater post-critical-care HRU; those over 80 had three times longer hospital readmissions than those younger than 50 (incidence rate ratio (IRR): 2.96, 95% CI: 2.84, 3.09). However, ED attendances were higher in those younger than 50. High comorbidity was associated with 22–62% greater post-critical-care HRU than no or low comorbidity. The most socioeconomically deprived quintile was associated with 24% more ED attendances (IRR: 1.24 [1.16, 1.32]) and 13% longer hospital stays (IRR: 1.13 [1.09, 1.17]) than the least deprived quintile. Critical care survivors had greater 1-year post-discharge HRU than non-critical inpatients, including 68% longer hospital stays (IRR: 1.68 [1.63, 1.74]). Critical care survivors, particularly those with older ages, high comorbidity, and socioeconomic deprivation, used significantly more primary and secondary care resources after discharge compared with their baseline and non-critical inpatients. Interventions are needed to ensure that key subgroups are identified and adequately supported.

19 February 2021 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
MPMark J Ponsford
Mark J Ponsford
RBRoss J Burton
Ross J Burton
LSLeitchan Smith
Leitchan Smith
PKPalwasha Khan
Palwasha Khan
RARobert Andrews
Robert Andrews
JUJonathan Underwood
Jonathan Underwood
Background The role of specific blood tests to predict poor prognosis in patients admitted with infection from SARS-CoV-2 remains uncertain. During the first wave of the global pandemic, an extended laboratory testing panel was integrated into the local pathway to guide triage and healthcare resource utilisation for emergency admissions. We conducted a retrospective service evaluation to determine the utility of extended tests (D-dimer, ferritin, high-sensitivity troponin I, lactate dehydrogenase and procalcitonin) compared with the core panel (full blood count, urea and electrolytes, liver function tests and C reactive protein). Methods Clinical outcomes for adult patients with laboratory-confirmed COVID-19 admitted between 17 March and 30 June 2020 were extracted, alongside costs estimates for individual tests. Prognostic performance was assessed using multivariable logistic regression analysis with 28-day mortality used as the primary endpoint and a composite of 28-day intensive care escalation or mortality for secondary analysis. Results From 13 500 emergency attendances, we identified 391 unique adults admitted with COVID-19. Of these, 113 died (29%) and 151 (39%) reached the composite endpoint. ‘Core’ test variables adjusted for age, gender and index of deprivation had a prognostic area under the curve of 0.79 (95% CI 0.67 to 0.91) for mortality and 0.70 (95% CI 0.56 to 0.84) for the composite endpoint. Addition of ‘extended’ test components did not improve on this. Conclusion Our findings suggest use of the extended laboratory testing panel to risk stratify community-acquired COVID-19 positive patients on admission adds limited prognostic value. We suggest laboratory requesting should be targeted to patients with specific clinical indications.

1 April 2021 in IJC Heart & Vasculature
Verified
Journal Article
Open access
LTLaura Tan
Laura Tan
SGSashiananthan Ganesananthan
Sashiananthan Ganesananthan
HHHani Huzaien
Hani Huzaien
HEHossam Elsayed
Hossam Elsayed
NSNisar Shah
Nisar Shah
ZYZaheer Yousef
Zaheer Yousef
Revision to cardiac resynchronisation therapy (CRT) in patients with existing pacemakers with worsening heart failure (HF) can improve symptoms and cardiac function. We identify factors that predict improvement in left ventricular ejection fraction (LVEF) within a year of CRT revision. We performed a retrospective study of 146 consecutive patients (16% female, mean age 73 ± 11 years, mean LVEF 27 ± 8%) undergoing revision to CRT (January 2012 to May 2018) in a single tertiary centre. LVEF was measured pre-revision and 3, 6 and 12 months post-upgrade. At 6 months, 68% of patients demonstrated improvement in LVEF (mean ΔLVEF + 6.7% ± 9.6). Compared to patients in atrial fibrillation (AF), patients with sinus rhythm had a greater improvement in LVEF at 6 months (sinus 8.4 ± 10.3% vs. AF 4.2 ± 8.0%, p = 0.02). Compared to ischaemic cardiomyopathy (ICM), patients with non-ischaemic cardiomyopathy (NICM) had a greater improvement in LVEF at 6 months (NICM 8.4 ± 9.8% vs ICM 4.8 ± 9.2%, p = 0.05). Patients with RV pacing ≥40% at baseline had a greater improvement in LVEF at 6 months (≥40% RV pacing 9.3 ± 10.2 vs. < 40% RV pacing 4.0 ± 7.4%, p = 0.01). All improvements were sustained over 12 months post-revision. There was no significant difference between genders, years between initial implant and revision, or previous device type. Our real-world experience supports current guidelines on CRT revision. NICM, ≥40% RV pacing and sinus rhythm are the main predictors of improvement in LVEF in patients who underwent CRT revision.

1 May 2021 in JACC
Verified
Journal Article
Closed access
LTLaura Tan
Laura Tan
SGSashiananthan Ganesananthan
Sashiananthan Ganesananthan
HHHani Huzaien
Hani Huzaien
HSHossam El Sayed
Hossam El Sayed
NSNisar Shah
Nisar Shah
ZYZaheer Yousef
Zaheer Yousef

11 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
MPMark J Ponsford
Mark J Ponsford
RBRoss J Burton
Ross J Burton
LSLeitchan Smith
Leitchan Smith
PKPalwasha Khan
Palwasha Khan
RARobert Andrews
Robert Andrews
JUJonathan Underwood
Jonathan Underwood
Background: The role of specific blood tests to predict poor prognosis in patients admitted with infection from SARS-CoV2 virus remains uncertain. During the first wave of the global pandemic, an extended laboratory testing panel was integrated into the local pathway to guide triage and healthcare resource utilisation for emergency admissions. We conducted a retrospective service evaluation to determine the utility of extended tests (D-dimer, ferritin, high-sensitivity troponin I, lactate dehydrogenase, procalcitonin) compared to the core panel (full blood count, urea & electrolytes, liver function tests, C-reactive protein). Methods: Clinical outcomes for adult patients with laboratory-confirmed COVID-19 admitted between 17 th March to 30 st June 2020 were extracted, alongside costs estimates for individual tests. Prognostic performance was assessed using multivariable logistic regression analysis with 28-day mortality used as the primary endpoint, and a composite of 28-day intensive care escalation or mortality for secondary analysis. Results: From 13,500 emergency attendances we identified 391 unique adults admitted with COVID-19. Of these, 113 died (29%) and 151 (39%) reached the composite endpoint. “Core” test variables adjusted for age, gender and index of deprivation had a prognostic AUC of 0.79 (95% Confidence Interval, CI: 0.67 to 0.91) for mortality and 0.70 (95% CI: 0.56 to 0.84) for the composite endpoint. Addition of “extended” test components did not improve upon this. Conclusion: Our findings suggest use of the extended laboratory testing panel to risk stratify community-acquired COVID-19-positive patients on admission adds limited prognostic value. We suggest laboratory requesting should be targeted to patients with specific clinical indications.

17 September 2024 in JMIR Preprints
Verified
Preprint
Open access
LTLaura Joo Peng Tan
Laura Joo Peng Tan
MNMoira Newiss
Moira Newiss
AMAlice McGee
Alice McGee
GMGuy Martin
Guy Martin
JNJean Nehme
Jean Nehme
BACKGROUND Long COVID is characterised by an array of physical and psychological symptoms that can be debilitating. Given the enormous number of individuals affected by long COVID, it presents a significant, and poorly understood emerging long-term medical and socioeconomic challenge. As such, there is a pressing need to develop and test new holistic and efficient approaches to whole-person treatment and rehabilitation at scale for patients with long COVID. OBJECTIVE To evaluate the effectiveness of a new human-centred, digital-first health platform - Avid - for the management of long COVID by examining its impact on participants quality of life scores and symptom severity in the short-term, and the platform’s usability and acceptability for end-users. METHODS 37 participants (35 female, mean age 46.5 years, 8.1% previously hospitalised with acute COVID) with long Covid were recruited into the Avid program. Avid is a human-centred, digital-first platform that delivers a 6-week program providing structured, personalised health coaching and tailored digital content aligned to specific weekly goals. The approach facilitates a standardised approach through evidenced-based treatment strategies, whilst simultaneously supporting personalised, adaptable care at scale. A quasi-experimental single arm pre-post intervention design was employed to evaluate the platform. The primary outcome measures were C19-YRSm and EQ5D-5L quality of life scores. Usability and acceptability of the program for participants was examined through Net Promoter Scores (NPS) and qualitative semi-structured interviews. RESULTS The Avid program led to significant and sustained improvements in C19-YRSm scores at week 6 (5.57 (SD 1.79) vs. 3.95 (SD 1.35), p=0.0001, mean improvement 41.0%); week 10 (5.07 (SD1.78) vs. 3.93 (1.18), p=0.0003, mean improvement 29.0%); and week 22 (5.08 (SD 1.68) vs. 3.88 (SD 1.13), p=0.0001, mean improvement 30.9%). The program also led to significant improvements in EQ5D-5L Index scores at week 6 (0.54 (SD 0.25) vs. 0.44 (SD 0.23) p=0.0005, mean improvement 25.0%); week 10 (0.51 (SD 0.25) vs. 0.44 (SD 0.24), p=0.0382, mean improvement 15.9%); and week 22 (0.54 (SD 0.23) vs. 0.46 (SD 0.23), p=0.0103, mean improvement 17.4%. The program was well received with 100% engagement and completion at 6 weeks. NPS scores showed 70% of participants were promoters of the program with a mean individual score of 8.64. CONCLUSIONS The pilot study indicates that the Avid platform is safe, feasible and effective. It produces significant and sustained improvements in the symptoms and severity of long COVID, and wider measures of quality of life in the short-term. These findings suggest that the approach may provide a clinically impactful, cost-effective, and scalable platform that can successfully manage the challenges of long COVID. The modular approach of the platform also readily facilitates its rapid development and expansion to address other health challenges and long-term conditions in the future.